Navigation Links
JDRF Announces Two Partnerships to Develop Stable, Pumpable Glucagon to Support Advanced Generation Artificial Pancreas Systems
Date:6/20/2013

f blood-glucose control, and previous studies supported by JDRF and others have shown that the addition of glucagon to insulin treatment in T1D reduces the frequency of hypoglycemia.

One major hurdle in developing an advanced generation, multi-hormonal artificial pancreas system is that commercially available glucagon does not remain stable; the powder and solution mix into a short-lived liquid form not suitable for long-term use in a pump. Xeris and LPI will develop two different approaches to making glucagon usable for infusion pumps.

Xeris—a specialty pharmaceutical company based in Austin, TX, focused on developing injectable therapeutics—will study its stable, room-temperature, and non-aqueous injectable glucagon (G-Pump™ Glucagon) to treat hypoglycemia. Clinical studies will take place at Oregon Health & Science University (OHSU) with two years of milestone-based funding from JDRF.

"Our partnership with JDRF enables us to move forward in pursuing an improved approach to controlling blood glucose levels  by enabling a fully closed loop system that addresses  both hyperglycemia and hypoglycemia," said Steve Prestrelski, Ph.D., chief executive officer at Xeris. "We look forward to working with JDRF to make this a successful program."

LPI—a drug formulation development company based in San Diego, CA—will use a unique, proprietary, solvent-free, glucagon nanoemulsion (Nano-G) to solubilize and stabilize the molecule, such that it is not vulnerable to degradation and remains biologically active. With milestone-based funding from JDRF for one year, LPI plans to begin clinical testing in the United States in 2014.

"LATITUDE is truly honored to partner with a prestigious and leading organization such as JDRF," said Andrew Chen, Ph.D., LPI's president. "Thi
'/>"/>

SOURCE JDRF
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
2. Valeant Pharmaceuticals Announces Exercise Of Over-Allotment Option
3. Haemonetics Announces Next Steps in Manufacturing Transformation
4. Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the Underwriter
5. BioCision Announces Two New U.S. Patents for Thermo-Conductive Products that Standardize Sample Handling in Laboratory Research
6. Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital
7. NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinsons Disease
8. Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes
9. Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock
10. Specialty Coating Systems Announces New Antimicrobial Parylene Technology
11. Apama Medical Announces Issuance Of Patent For Low Profile Electrodes For Use On Balloons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- Echo Therapeutics, Inc. (NASDAQ: ECTE ... permeation, continuous glucose monitoring and associated technologies, today ... been appointed Chief Executive Officer effective December 22, ... of experience in the medical device, pharmaceutical and ... Vice President, Business Development, Otsuka Pharmaceuticals as well as ...
(Date:12/24/2014)... , December 24, 2014 ... on Global Disposable Syringe Industry of 178 ... online business intelligence library. The ... Syringe Industry is a professional and deep ...  For overview analysis, the report introduces Disposable ...
(Date:12/24/2014)... 2014  Lockton Dunning Benefits, the ... the addition of Vice President Kim Foerster ... Pharmacy Consulting team, Excelsior Solutions. ... to the position.  Most recently, she worked as ... Specialty Pharmacy, where she has held various managerial ...
Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5Kim Foerster Joins Lockton Companies 2
... Arthritis Foundation,the leading health organization addressing the needs ... that Amgen and Wyeth,Pharmaceuticals, co-marketers of Enbrel (R) ... 2008 Arthritis Walk (R)., "The Arthritis Foundation ... funds to prevent, control and cure arthritis, the,nation,s ...
... in, Achieving Red Blood Cell Transfusion Independence, Hematologic Improvement ... ... the 49th American Society of Hematology (ASH) Meeting, ATLANTA, ... interim data from a Phase 2 clinical trial,evaluating three alternative ...
Cached Medicine Technology:Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R) 2Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R) 3Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R) 4MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 2MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 3MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 4MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 5MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 6
(Date:12/26/2014)... “Many people become overwhelmed by the ... issues and phone calls with insurance companies,” The Jones ... their free eBook on pedestrian and bicycle accidents ... and bicycle auto accident claims assures the injured individual ... professionally handling their case while they focus on recovering. ...
(Date:12/26/2014)... December 26, 2014 Parker & ... the best in heating, cooling and plumbing contractor ... hour emergency services in 2014 with regard to ... that Arizona is known for its incredibly hot ... understands the intricacies and details of a wide ...
(Date:12/25/2014)... 2014 The report “Nintedanib (Colorectal ... focuses on the current treatment landscape, unmet needs, ... cancer market. Stivarga is a drug which is ... cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), an ... refractory CRC in the US, Europe, and Japan. ...
(Date:12/25/2014)... 26, 2014 Recently, iFitDress.com, the popular online ... has announced its new selection of black one-shoulder cocktail ... sale now; they are available at discounted prices, up to ... promotion will last for three weeks only. You know, we ... who are interested in our new items can visit our ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... , CUPERTINO, Calif., Sept. 17 DURECT ... scheduled to present at two upcoming healthcare conferences. , , ... , Matt Hogan, Chief Financial Officer, will ... on Wednesday, September 23rd at 10:30 a.m. Eastern Time. A ...
... , , MOUNTAIN VIEW, ... first and leading providers of kidney dialysis services and a ... The Polycystic Kidney Disease Foundation,s "Pathway to a Cure" walk ... held Sunday, September 20, 2009 at The Capital Building, 1315 ...
... , , , ... Somanetics Corporation (Nasdaq: SMTS ) today reported net revenues ... percent increase from $12.4 million in the same period of 2008. For ... $35.5 million from $33.8 million. , , U.S. net revenues ...
... , , , ... of a plan to expand its brand, Nutrisystem Inc., (Nasdaq: ... market Nutrisystem J Diet in Japan. Capitalizing on the success of Nutrisystem ... North America, House Foods will begin to sell Nutrisystem J Diet in ...
... , , , ... is an important time for families and eyesight, as many schools ... With the start of a new school year, it,s also a ... the environment and establish every day green habits. With this in ...
... , , , ... management provider Avizent announced today that Adrienne Paler, Executive Vice President ... the Disability Management Employer Coalition (DMEC). , , ... to the organization. Ms. Paler worked to write and enhance ...
Cached Medicine News:Health News:DURECT Corporation to Participate in Upcoming Healthcare Conferences 2Health News:Satellite Healthcare Helps Support the Cure for Kidney Disease in Sacramento 2Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 2Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 3Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 4Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 5Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 6Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 7Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 8Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 9Health News:Nutrisystem and House Foods Announce Licensing Agreement To Market Nutrisystem J Diet in Japan 2Health News:Nutrisystem and House Foods Announce Licensing Agreement To Market Nutrisystem J Diet in Japan 3Health News:Back to School Season is Time for New Green Routines 2Health News:Back to School Season is Time for New Green Routines 3Health News:Avizent Executive Earns DMEC Partnership Award 2
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
The Antibacterial Personal Catheter® features a unique silicone composition that provides an antibacterial coated soft outer layer of silicone combined with a firm inner layer....
The Uro San® Plus male external catheter is a latex catheter with a double-sided adhesive and Shield Skin Protective Dressing....
... Mentor Freedom Pak Seven Starter ... week's supply of Freedom Clear ... all 100% latex-free ... for your convenience and comfort. ...
Medicine Products: